Celcuity reports Q4 EPS (69c), consensus (44c)

"We achieved a number of critical milestones in the fourth quarter. Most importantly, we dosed the first patient in our Phase 3 VIKTORIA-1 trial of gedatolisib in advanced breast cancer. This milestone, in turn, triggered the closing of our $100 million PIPE financing and a $20 million drawdown on our term loan," said Brian Sullivan, CEO. "These financings significantly strengthen our balance sheet and are expected to provide the capital we need to fund operations through 2025."